A pharmaceutical company is commissioning a small server room that houses systems supporting clinical trial data. The room contains tape archives, paper-based standard operating procedures in a wall cabinet, and approximately twenty staff who work in adjacent open-plan offices. The facilities team has costed three fire suppression options and asks the security manager to recommend the BEST primary suppression for the room itself.
- AA pre-action sprinkler system charged with water only when smoke detection trips, with manual abort stations on the room exit.
- BA clean agent gaseous system using an inert gas blend designed to the local concentration and egress standards, with audible and visual pre-discharge warnings. Correct
- CA high-pressure carbon dioxide total flooding system sized to the room volume with a thirty-second pre-discharge delay.
- DA dry chemical system using monoammonium phosphate powder discharged through ceiling nozzles across the room.
Why A is wrong: Pre-action sprinklers are safer than wet pipe in IT spaces, but water discharge will still damage tapes and electronics. Where a clean agent is justified by the asset value, pre-action is normally a secondary, life-safety backstop rather than the primary choice.
Why B is correct: A clean agent system suppresses fire without water damage to tapes, media, or running electronics, and is designed to remain within safe oxygen and exposure limits for occupants when local egress and warning requirements are met. For a small, occupied IT room with high-value media, this is the BEST primary suppression.
Why C is wrong: Carbon dioxide is effective but lethal at design concentrations and is not appropriate as the primary system in a normally occupied space. Modern codes restrict its use to unoccupied risks, so it fails the occupancy constraint of this scenario.
Why D is wrong: Dry chemical powder contaminates electronics and media, is extremely difficult to clean up, and is rarely chosen for clean IT environments. It would suppress fire but at unacceptable cost to the trial data and equipment.